Stem-completion tasks (indirect, direct inclusion and exclusion) are differently affected by equipotent doses of lorazepam and flunitrazepam
| dc.contributor.author | Pompeia, S. | |
| dc.contributor.author | Bueno, OFA | |
| dc.contributor.author | Galduroz, JCF | |
| dc.contributor.author | Tufik, S. | |
| dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
| dc.date.accessioned | 2016-01-24T12:34:04Z | |
| dc.date.available | 2016-01-24T12:34:04Z | |
| dc.date.issued | 2003-10-01 | |
| dc.description.abstract | This study was designed to explore the effects on performance in stem-completion tasks of two benzodiazepines (BZ) in equipotent doses: lorazepam, a drug that atypically disrupts perceptual priming, and flunitrazepam, a compound with standard BZ effects. the study followed a placebo-controlled, double-blind, parallel-group design. Thirty-six young and healthy subjects carried out three completion tasks at theoretical peak-plasma concentrations of drugs: (a) indirect tasks, in which the subjects were instructed to complete stems with the first word that came to mind; (b) direct inclusion tasks/cued recall, in which the participants had to try to use words seen at study as completions; and (c) direct exclusion tasks, in which words seen at study were to be avoided. the PDP was applied to the results in the inclusion and exclusion tasks, to obtain indices of explicit/controlled (C) and implicit/automatic (A) memory. the C index was lowered by both BZs and A was equivalent in all treatments, confirming the general amnestic action of BZs. However, lorazepam led to decreases in completions in the indirect and inclusion tasks, while flunitrazepam impaired performance in the exclusion task. the qualitative differences between the drugs in their effects on performance suggest that these BZs may lead to differences in response bias. Copyright (C) 2003 John Wiley Sons, Ltd. | en |
| dc.description.affiliation | UNIFESP, Dept Psicobiol, BR-04024002 São Paulo, Brazil | |
| dc.description.affiliationUnifesp | UNIFESP, Dept Psicobiol, BR-04024002 São Paulo, Brazil | |
| dc.description.source | Web of Science | |
| dc.format.extent | 541-549 | |
| dc.identifier | http://dx.doi.org/10.1002/hup.515 | |
| dc.identifier.citation | Human Psychopharmacology-clinical and Experimental. Chichester: John Wiley & Sons Ltd, v. 18, n. 7, p. 541-549, 2003. | |
| dc.identifier.doi | 10.1002/hup.515 | |
| dc.identifier.issn | 0885-6222 | |
| dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/27427 | |
| dc.identifier.wos | WOS:000185958800006 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley-Blackwell | |
| dc.relation.ispartof | Human Psychopharmacology-clinical and Experimental | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.license | http://olabout.wiley.com/WileyCDA/Section/id-406071.html | |
| dc.subject | benzodiazepines | en |
| dc.subject | memory | en |
| dc.subject | stem-completion | en |
| dc.subject | lorazepam | en |
| dc.subject | flunitrazepam | en |
| dc.subject | process-dissociation procedure | en |
| dc.title | Stem-completion tasks (indirect, direct inclusion and exclusion) are differently affected by equipotent doses of lorazepam and flunitrazepam | en |
| dc.type | info:eu-repo/semantics/article |